Non-Hodgkin lymphoma

Victory Against Bayer! Williams Hart & Boundas Wins Against Monsanto's Roundup Weedkiller

Retrieved on: 
Wednesday, December 13, 2023
Legal, Professional Services, Risk, Recurrence, PC, Bounda, Multimedia, Al Stewart, Non-Hodgkin lymphoma, William Hart (priest), Diagnosis, Bayer

Plaintiff Kelly Martel was represented by John Boundas, partner at Williams Hart & Boundas, and Scott Frieling of Al Stewart, PC, Walt Cubberly, Margret Lecocke and Conor Cathey of Williams Hart & Boundas, and Rosemary Pinto of Feldman and Pinto.

Key Points: 
  • Plaintiff Kelly Martel was represented by John Boundas, partner at Williams Hart & Boundas, and Scott Frieling of Al Stewart, PC, Walt Cubberly, Margret Lecocke and Conor Cathey of Williams Hart & Boundas, and Rosemary Pinto of Feldman and Pinto.
  • Williams Hart & Boundas Wins Against Monsanto's Roundup Weedkiller (Photo: Business Wire)
    Ms. Martel fought through her diagnosis, treatment, and recurrence the same way she persevered through two depositions and a 16-day trial.
  • Ms. Martel’s case moved quickly under the Philadelphia Mass Tort Program, which Williams Hart & Boundas originated earlier this year with Philadelphia lawyer Rosemary Pinto and other firms representing Roundup plaintiffs.
  • Williams Hart & Boundas lawyers John Boundas , Margret Lecocke , Walt Cubberly , Conor Cathey , and the firm's trial support team look forward to continuing our representation of Roundup clients in trials across the country in the upcoming year.

Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

Retrieved on: 
Monday, December 11, 2023
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, BCL2, Fever, MYC, Progression-free survival, ASH, Aes, CRS, EFS, B-cell lymphoma, Headache, Cytopenia, Non-Hodgkin lymphoma, Patient, Abstract, PFS, DOR, BCL6, Histology, ORR, MD, Survival, Doctor of Philosophy, Drug, Society, OS, Confidence interval, Axicabtagene ciloleucel, SVP, Cytokine release syndrome, Pharmaceutical industry

“Patients with high-risk, large B-cell lymphoma, have a poor prognosis with currently available therapies,” said Julio C. Chavez, MD, lead investigator, Moffitt Cancer Center.

Key Points: 
  • “Patients with high-risk, large B-cell lymphoma, have a poor prognosis with currently available therapies,” said Julio C. Chavez, MD, lead investigator, Moffitt Cancer Center.
  • “This is particularly true of patients with double- or triple-hit histology, who have a median survival of under a year with standard treatment.
  • Prolonged cytopenias of any grade (present Day ≥30 post-infusion) occurred in 9 patients (n=7 neutrophil count decreased) and were resolved by data cutoff.
  • Among treated patients, the in vivo Yescarta expansion and persistence profiles are consistent with previous observations.

Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bristol Myers Squibb, Safety, NYSE, Non-Hodgkin lymphoma, Pneumonia, ASH, Ikaros, Rituximab, Patient, Cell, Thrombocytopenia, BMY, Lymphoma, Death, CMR, DL, Neutropenia, ORR, Anemia, Society, NK, Febrile neutropenia, Pharmaceutical industry, Fever, DL-1, Hematology

Bristol Myers Squibb (NYSE: BMY) announced the results of two early studies evaluating combinations of potential first-in-class CELMoD™ agent golcadomide in non-Hodgkin lymphomas.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) announced the results of two early studies evaluating combinations of potential first-in-class CELMoD™ agent golcadomide in non-Hodgkin lymphomas.
  • These data are being presented in separate posters ( #4459 , #4496 , #1631 ) at the 2023 American Society of Hematology (ASH) Annual Meeting from December 9-12.
  • “In the studies being presented at ASH 2023, golcadomide has shown potential warranting further evaluation in patients with first-line and previously treated large B-cell lymphomas.
  • There were 4 deaths on treatment during the study with one considered related to the study treatment.

Stem Cell Technologies and Applications Global Market Report 2023-2033 - Growing Government Support Driving Market Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, December 4, 2023
Biotechnology, Health, Oncology, Stem Cells, B cell, Research, Non-Hodgkin lymphoma, Therapy, Sickle cell disease, Investment, Kite Pharma, Insurance, Patient, FDA, IPO, NIH, Growth, Knowledge, Government, Mobile phone, Veterinary medicine

World revenue for the Stem Cell Technologies and Applications Market is forecast to surpass US$10 billion in 2023.

Key Points: 
  • World revenue for the Stem Cell Technologies and Applications Market is forecast to surpass US$10 billion in 2023.
  • Growing government support for stem cell research and development is fuelling the growth of stem cell companies.
  • The following are a few specific advances in stem cell companies that happened in 2022:
    Clinical studies for stem cell therapies: In 2022, several stem cell therapies were introduced into clinical trials.
  • Regulatory clearances for stem cell companies: In 2022, a number of stem cell companies were granted regulatory approvals.

Global CD19 Antibody Market and Clinical Pipeline Outlook 2023-2028: A $10 Billion+ Market by 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 22, 2023
Health, Pharmaceutical, Research, Antibody, Immune system, Non-Hodgkin lymphoma, Therapy, Lymphoid leukemia, Loncastuximab tesirine, Scleroderma, CRS, JW, IND, Tafasitamab, Tisagenlecleucel, B-cell lymphoma, Patient, Systemic scleroderma, CD19, Blinatumomab, FDA, Lupus, Acute leukemia, SLE, Chronic lymphocytic leukemia, Novartis, Sjögren syndrome, Neurotoxicity, Quality of life, NHL, Fast Track, ALL, Cytokine release syndrome, CLL, Vaccine, Pharmaceutical industry, Amgen

The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • This can be attributed to the rapid regulatory approvals, and the current pipeline of investigational CD19-targeting therapies shows potential for a further surge of this market cap.
  • CD19-targeting therapies have made a significant impact on the clinical landscape of cancer treatment.
  • Global CD19 Antibody Market and Clinical Pipeline Outlook 2028 Report Highlights:
    Global CD19 Antibody Market Opportunity: > USD 10 Billion By 2028
    Commercially Approved CD 19 Antibodies: 10 Antibodies
    Comprehensive Insights On CD19 Antibodies In Clinical Trials: > 190 Antibodies
    Global CD19 Antibodies Clinical Trials By Company, Indication and Phase

Nachawati Law Group: Latest Verdict in Roundup Weedkiller Case Reinforces Need for Action by Manufacturers

Retrieved on: 
Monday, November 20, 2023
Class Action Lawsuit, Professional Services, Legal, Fears Nachawati, Union Investment, Non-Hodgkin lymphoma, Jury, Cancer, Pharmaceutical industry, Bayer

The $1.56 billion jury verdict in Missouri Friday marks the fourth consecutive trial result in favor of Roundup plaintiffs in recent months.

Key Points: 
  • The $1.56 billion jury verdict in Missouri Friday marks the fourth consecutive trial result in favor of Roundup plaintiffs in recent months.
  • “I am pleased to see jurors ruling in favor of those who have been hurt by this dangerous product,” said Nachawati Law Group founder Majed Nachawati , whose Dallas-based firm represents more than 5,000 cancer victims against the manufacturers.
  • According to trial evidence, Monsanto for decades downplayed known cancer risks associated with exposure to glyphosate, the main ingredient in Roundup.
  • Earlier this month, Union Investment, one of Bayer's top shareholders, called on the company to resolve the cases with the cancer victims.

AbelZeta Announces Amendment to Worldwide Collaboration and License Agreement with Janssen to Include China

Retrieved on: 
Thursday, December 14, 2023
Johnson & Johnson, IND, Disease, Investigational New Drug, Non-Hodgkin lymphoma, Janssen, NHL, Pharmaceutical industry

ROCKVILLE, Md. and SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, today announced an amendment of its worldwide collaboration and license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company. Under the amended agreement, Janssen will have the option to obtain exclusive commercialization rights in China for CD20-directed chimeric antigen receptor T (CAR-T) C-CAR039 and C-CAR066, which are being studied for the treatment of Non-Hodgkin Lymphoma (NHL). 

Key Points: 
  • and SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, today announced an amendment of its worldwide collaboration and license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company.
  • Under the amended agreement, Janssen will have the option to obtain exclusive commercialization rights in China for CD20-directed chimeric antigen receptor T (CAR-T) C-CAR039 and C-CAR066, which are being studied for the treatment of Non-Hodgkin Lymphoma (NHL).
  • "The Centre for Drug Evaluation in China has approved the Investigational New Drug (IND) application for C-CAR039, and we are currently conducting the Phase 1b study.
  • Under the terms of the agreement, Janssen will pay AbelZeta Pharma an option exercise fee, and AbelZeta Pharma is eligible to receive commercialization and sales milestones.

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Retrieved on: 
Tuesday, December 12, 2023
CNS, Stomatitis, BTK, History, Patient, PCNSL, BID, Symantec Endpoint Protection, Non-Hodgkin lymphoma, Infrared spectroscopy correlation table, NHL, Syncope, Pharmaceutical industry, Curie Institute (Paris)

LEXINGTON, Mass., Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients.

Key Points: 
  • LEXINGTON, Mass., Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients.
  • "We are very pleased with the initial emavusertib/ibrutinib combination data from the TakeAim Lymphoma study.
  • As of October 12th, the TakeAim Lymphoma trial has enrolled and treated 19 Non-Hodgkin Lymphoma (NHL) patients, with a combination of emavusertib and ibrutinib; with emavusertib doses ranging from 100 mg to 300 mg BID.
  • These data underscore the potential of emavusertib to re-sensitize patients to BTKi therapy, marking a significant advancement in Non-Hodgkin Lymphoma treatment.

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting

Retrieved on: 
Tuesday, December 12, 2023
Medicine, Drug, Safety, NYSE, Arrhythmia, BTK, CTCAE, MCL, Lymphoid leukemia, Progression-free survival, ASH, Cytopenia, Dana–Farber Cancer Institute, Lymphocytosis, Bleeding, Clinical trial, Fatigue, Non-Hodgkin lymphoma, Rituximab, Patient, Abstract, Mantle cell lymphoma, PFS, SLL, Lymphoma, Infection, FDA, DOR, LLY, Exposition, Neutropenia, PVR, ORR, Lilly, Eli Lilly and Company, Chronic lymphocytic leukemia, Nausea, Diarrhea, Pulmonary toxicity, IRC, Chills, Society, OS, NHL, PV, HIV disease progression rates, Venetoclax, Pharmaceutical industry, Dietary supplement, CLL

These data, which were presented in oral and poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, continue to support the role of pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL).

Key Points: 
  • These data, which were presented in oral and poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, continue to support the role of pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL).
  • The labeling for pirtobrutinib contains warnings and precautions for infections, hemorrhage, cytopenias, cardiac arrhythmias, second primary malignancies, and embryo-fetal toxicity.
  • The BRUIN Phase 1/2 clinical trial is evaluating pirtobrutinib in patients previously treated for MCL, CLL/SLL, or other non-Hodgkin lymphomas (NHL).
  • All presentations of safety and efficacy data from the BRUIN Phase 1/2 trial utilized a cutoff date of May 5, 2023.

Bio Ascend, a Vaniam Group Company, Reconvenes Inaugural Class of the "Academy of Next Wave of Investigators™" in CLL and NHL

Retrieved on: 
Monday, December 11, 2023
Leukemia Research, Associate, Research, Associate professor, SAN, Senior, Non-Hodgkin lymphoma, Weill Cornell Medicine, ASH, Leukemia, Emory University, Dana–Farber Cancer Institute, Clinical research, Chairperson, Patient, Faculty, Indolent lymphoma, Division, Mentorship, Chronic lymphocytic leukemia, University, Winship Cancer Institute, Oncology, Columbia University, US-China strategic engagement, MMSc, Society, NHL, MD Anderson Cancer Center, Innovation, CLL, Health, Next wave, Management, Hospital, Hematology, MD, Lymphoma

SAN DIEGO, Dec. 11, 2023 /PRNewswire/ -- Bio Ascend, Vaniam Group's medical education company, this past weekend reconvened the inaugural class of its Academy of Next Wave of Investigators™ at a networking reception during the 65th annual American Society of Hematology (ASH) annual meeting. These young clinical investigators are participating in a year-long opportunity to engage in live and virtual career development seminars with international thought leaders in the fields of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

Key Points: 
  • These young clinical investigators are participating in a year-long opportunity to engage in live and virtual career development seminars with international thought leaders in the fields of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
  • "This next generation of hematology leaders is at a critical moment in their promising careers," said Kraig Steubing, Head of Bio Ascend and Senior Vice President of Strategic Engagement at Vaniam Group.
  • We wholeheartedly thank the members of our inaugural class, our distinguished faculty, and the program's sponsors."
  • In the subsequent months, the early-career investigators have been meeting regularly with their assigned mentors, prior to reconvening in person at the ASH annual meeting this past weekend.